JPH059111A - Fat emulsion and its production - Google Patents

Fat emulsion and its production

Info

Publication number
JPH059111A
JPH059111A JP3222031A JP22203191A JPH059111A JP H059111 A JPH059111 A JP H059111A JP 3222031 A JP3222031 A JP 3222031A JP 22203191 A JP22203191 A JP 22203191A JP H059111 A JPH059111 A JP H059111A
Authority
JP
Japan
Prior art keywords
fat emulsion
fat
emulsifier
emulsion
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP3222031A
Other languages
Japanese (ja)
Other versions
JP2950348B2 (en
Inventor
Yoshihito Nawa
義仁 名和
Tadaaki Inoue
忠昭 井上
Hideto Kodaira
英人 小平
Ryoichiro Murashima
良一郎 村島
Shunichi Abe
俊一 阿部
Kazumasa Yokoyama
和正 横山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26461431&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH059111(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp Japan filed Critical Green Cross Corp Japan
Priority to JP3222031A priority Critical patent/JP2950348B2/en
Priority to DK96115944T priority patent/DK0752243T3/en
Priority to EP95104553A priority patent/EP0671166B1/en
Priority to EP92107054A priority patent/EP0510687B1/en
Priority to DK95104553T priority patent/DK0671166T3/en
Priority to CA002067062A priority patent/CA2067062C/en
Priority to DE69232811T priority patent/DE69232811T2/en
Priority to ES92107054T priority patent/ES2181669T3/en
Priority to DE69232957T priority patent/DE69232957T2/en
Priority to ES96115944T priority patent/ES2188704T3/en
Priority to EP96115944A priority patent/EP0752243B1/en
Priority to DE69233437T priority patent/DE69233437T2/en
Priority to DK92107054T priority patent/DK0510687T3/en
Priority to TW081103293A priority patent/TW320563B/zh
Priority to KR1019920007018A priority patent/KR920019370A/en
Publication of JPH059111A publication Critical patent/JPH059111A/en
Priority to US08/475,812 priority patent/US5972367A/en
Priority to US08/478,970 priority patent/US5674527A/en
Priority to US08/589,207 priority patent/US5626880A/en
Priority to US09/244,931 priority patent/US6475506B1/en
Priority to KR1019990023090A priority patent/KR100244997B1/en
Publication of JP2950348B2 publication Critical patent/JP2950348B2/en
Application granted granted Critical
Priority to KR1019990062610A priority patent/KR100489158B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE:To obtain a fat emulsion, excellent in stability in sterilization, preservation and mixing with other transfusion solutions and useful for supplying nutriments, and a method for producing the aforementioned fat emulsion. CONSTITUTION:A fat emulsion is obtained by including 0.01-5.0wt./vol.% content of an emulsifying agent and regulating the average particle diameter to >=0.17mum. Furthermore this method for producing the fat emulsion of this invention is to produce the aforementioned fat emulsion by the coexistence of glycerol and/or glucose in preparing the emulsion. According to this invention, the average particle diameter of the fat emulsion is regulated to <=0.17mum and the stability of the fat emulsion is remarkably improved. A good emulsified state can simultaneously be kept in mixing with other transfusion solutions. The fat emulsion having the above-mentioned characteristics can simply and surely be prepared according to the method for production of this invention.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は脂肪乳剤及びその製造法
に関し、より詳細には安定性を改良した栄養補給用脂肪
乳剤及びその製造法に関する。
FIELD OF THE INVENTION The present invention relates to a fat emulsion and a method for producing the same, and more particularly to a fat emulsion for nutritional supplement having improved stability and a method for producing the same.

【0002】[0002]

【従来の技術】従来、患者の生命の維持において、経口
栄養、経管栄養が不可能であったり、あるいは不十分な
状態であったり、又はそれらが可能ではあっても患者の
消化吸収機能が著しく不良であったり、更には食物が消
化管を通過するのが原疾患の悪化につながるような病態
の場合には、栄養補給のために、経静脈的に輸液の投与
が行われている。このような輸液製剤としては、還元糖
等の糖類を含有する糖輸液、必須アミノ酸等を含有する
アミノ酸輸液、ミネラル類を含有する電解質輸液、植物
油乳剤等を含有する脂肪乳剤、混合ビタミン剤などが市
販されており、これらの輸液製剤を患者の症状などに合
わせて、使用時に適宜混合して用いられている。
2. Description of the Related Art Conventionally, in maintaining the life of a patient, oral nutrition and tube feeding are impossible or inadequate, or even if they are possible, the digestive absorption function of the patient is In the case of extremely poor conditions, or in the case of a pathological condition in which the passage of food through the digestive tract leads to aggravation of the original disease, intravenous administration of an infusion is performed for nutritional supplementation. Such infusion preparations include sugar infusions containing sugars such as reducing sugars, amino acid infusions containing essential amino acids and the like, electrolyte infusions containing minerals, fat emulsions containing vegetable oil emulsions, mixed vitamin preparations and the like. It is commercially available, and these infusion preparations are appropriately mixed and used at the time of use according to the symptoms of the patient.

【0003】[0003]

【発明が解決しようとする課題】上記の各種輸液製剤の
うち、脂肪乳剤は、通常、植物油等の油脂を乳化剤を用
いて水に分散させて水中油型乳剤とすることにより調製
されるが、脂肪乳剤は不安定で、加熱滅菌時や保存中に
経時的に油脂粒子の粗大化を生じ易い。また、上述のよ
うに、各種輸液剤は使用時に混合して用いられるが、輸
液製剤の使用時における混合は作業従事者にとって煩雑
な操作であり、なによりも混合時に菌汚染の問題があ
る。このような問題から、脂肪乳剤と他の輸液製剤とを
事前に混合した輸液製剤が検討されているが、脂肪乳剤
は不安定であり、混合により乳剤の崩壊、油脂粒子の粗
大化、相分離等を生じ易く、実用上種々の問題がある。
特に、脂肪乳剤に糖類を配合した製剤においては、両液
の比重の相違から相分離が起り易い。上記のように、脂
肪乳剤は安定性が劣り、また他の輸液剤との混合適性に
欠ける。特に脂肪乳剤に糖類を配合した輸液製剤におい
ては、脂肪乳剤の相分離が生じ易く、長期にわたり安定
な製剤を得られないという問題がある。そのため、安定
性に優れた脂肪乳剤が切望されている。本発明者らは上
記事情に鑑み、脂肪乳剤の安定化について鋭意検討した
結果、脂肪乳剤の平均粒子径を小さくすることにより脂
肪乳剤の安定性が著しく向上し、相分離などが起こりに
くくなることを見出した。本発明は上記の知見に基づい
てなされたものである。脂肪乳剤の平均粒子径を小さく
するには、通常、乳化剤の使用量を多くすることが行わ
れるが、リン脂質等の乳化剤の使用量を多くすると、脂
肪乳剤中の遊離脂肪酸含量が増大する。遊離脂肪酸は、
脂肪乳剤の毒性の原因となるおそれがあるので、脂肪乳
剤中の遊離脂肪酸含量は極力低下させる必要があり、そ
のため多量の乳化剤を使用することはできない。本発明
は上記従来技術の問題点を解消するために創案されたも
ので、本発明は安定性に優れた脂肪乳剤及びその製造法
を提供することを目的とする。
Of the above various infusion preparations, a fat emulsion is usually prepared by dispersing an oil or fat such as vegetable oil in water using an emulsifier to obtain an oil-in-water emulsion. The fat emulsion is unstable, and the fat and oil particles are likely to coarsen with time during heat sterilization and during storage. Further, as described above, various infusion agents are mixed and used at the time of use, but mixing at the time of use of the infusion preparation is a complicated operation for a worker, and above all, there is a problem of bacterial contamination at the time of mixing. Due to these problems, infusion preparations in which fat emulsions and other infusion preparations have been mixed in advance have been studied, but fat emulsions are unstable, and emulsions are disintegrated by mixing, coarsening of oil and fat particles, and phase separation. And so on, and there are various problems in practical use.
In particular, in a preparation in which a saccharide is mixed with a fat emulsion, phase separation easily occurs due to the difference in specific gravity between the two liquids. As described above, the fat emulsion is inferior in stability and lacks compatibility with other infusion agents. In particular, in an infusion preparation in which a saccharide is mixed with a fat emulsion, there is a problem that phase separation of the fat emulsion easily occurs and a stable preparation cannot be obtained for a long period of time. Therefore, a fat emulsion having excellent stability has been earnestly desired. In view of the above circumstances, the present inventors have diligently studied stabilization of a fat emulsion, and as a result of reducing the average particle diameter of the fat emulsion, the stability of the fat emulsion is significantly improved and phase separation and the like are less likely to occur. Found. The present invention has been made based on the above findings. In order to reduce the average particle size of the fat emulsion, usually, the amount of the emulsifier used is increased. However, if the amount of the emulsifier such as phospholipid used is increased, the free fatty acid content in the fat emulsion increases. Free fatty acids are
It is necessary to reduce the free fatty acid content in the fat emulsion as much as possible, since it may cause toxicity of the fat emulsion, and therefore a large amount of emulsifier cannot be used. The present invention was devised to solve the above-mentioned problems of the prior art, and an object of the present invention is to provide a fat emulsion having excellent stability and a method for producing the same.

【0004】[0004]

【課題を解決するための手段】上記の課題を解決するた
め、本発明者らは平均粒子径の小さい栄養補給用脂肪乳
剤を得るべく鋭意検討した結果、脂肪乳剤の調製時にグ
リセリン及び/又はブドウ糖を共存させると脂肪乳剤の
平均粒子径を小さくすることができ、それにより脂肪乳
剤の安定性が著しく向上し、相分離などが起こりにくく
なることを見出して本発明を完成した。即ち、本発明の
脂肪乳剤は、油脂を乳化剤を用いて乳化させた栄養補給
用脂肪乳剤であって、乳化剤含量が0.01〜5.0W/V%であ
り、脂肪乳剤の平均粒子径が0.17μm以下のものであ
る。また、本発明の脂肪乳剤の製造方法は、上記脂肪乳
剤の製造法であり、油脂を、グリセリン及びブドウ糖か
ら選ばれた1種又は2種とともに乳化剤を用いて乳化
し、平均粒子径が0.17μm以下の脂肪乳剤を得るもので
ある。
In order to solve the above problems, the inventors of the present invention have conducted extensive studies to obtain a fat emulsion for nutritional supplementation having a small average particle size, and as a result, glycerin and / or glucose were prepared at the time of preparation of the fat emulsion. The present invention has been completed based on the finding that the coexistence of (1) and (2) can reduce the average particle size of the fat emulsion, thereby significantly improving the stability of the fat emulsion and making phase separation less likely to occur. That is, the fat emulsion of the present invention is a nutritional supplement fat emulsion obtained by emulsifying fats and oils with an emulsifier, the emulsifier content is 0.01 to 5.0 W / V%, and the average particle diameter of the fat emulsion is 0.17 μm or less. belongs to. Further, the method for producing a fat emulsion of the present invention is the method for producing a fat emulsion described above, wherein fats and oils are emulsified with an emulsifier together with one or two selected from glycerin and glucose, and the average particle diameter is 0.17 μm. The following fat emulsion is obtained.

【0005】本発明は上記の構成からなり、本発明の脂
肪乳剤及び本発明の製造法により得られる脂肪乳剤は、
油脂を乳化剤を用いて水に分散させて調製された水中油
型乳剤であって、平均粒子径が0.17μm以下の栄養補給
用脂肪乳剤である。上記の油脂としては食用油であれば
いずれの油脂も使用でき、例えば、植物油(例えば、大
豆油、綿実油、サフラワー油、トウモロコシ油、ヤシ
油、シソ油、エゴマ油等)、魚油(例えば、タラ肝油
等)、中鎖脂肪酸トリグリセリド[例えば、パナセート
(商品名)、ODO(商品名)等]及び化学合成トリグリ
セリド類[例えば、2-リノレオイル-1,3-ジオクタノイ
ルグリセロール(8L8)、2-リノレオイル-1,3-ジデカノイ
ルグリセロール(10L10)等のChemically defined trigly
cerides]から選ばれた1種又は2種以上の油脂が好適
に用いられる。また、乳化剤としては医薬製剤に使用さ
れる乳化剤であればいずれの乳化剤も用いることがで
き、例えば、卵黄リン脂質、水素添加卵黄リン脂質、大
豆リン脂質、水素添加大豆リン脂質及び非イオン性界面
活性剤[例えば、プルロニックF68、HCO-60(いずれも
商品名)等]から選ばれた1種又は2種以上の乳化剤が
好適に用いられる。特に好ましくは、油脂として大豆
油、乳化剤として卵黄リン脂質を用いた脂肪乳剤が挙げ
られる。
The present invention has the above-mentioned constitution, and the fat emulsion of the present invention and the fat emulsion obtained by the production method of the present invention are
An oil-in-water emulsion prepared by dispersing fats and oils in water using an emulsifier, which is a fat emulsion for nutritional supplement having an average particle size of 0.17 μm or less. As the above-mentioned oil and fat, any oil and fat can be used as long as it is an edible oil, for example, vegetable oil (for example, soybean oil, cottonseed oil, safflower oil, corn oil, coconut oil, perilla oil, perilla oil, etc.), fish oil (for example, Cod liver oil, etc.), medium-chain fatty acid triglycerides [eg, panacetate
(Trade name), ODO (trade name), etc. and chemically synthesized triglycerides [for example, 2-linoleoyl-1,3-dioctanoylglycerol (8L8), 2-linoleoyl-1,3-didecanoylglycerol (10L10 ) Etc. Chemically defined trigly
Cerides], one or more kinds of fats and oils are preferably used. Further, as the emulsifier, any emulsifier can be used as long as it is an emulsifier used in pharmaceutical preparations, for example, egg yolk phospholipids, hydrogenated egg yolk phospholipids, soybean phospholipids, hydrogenated soybean phospholipids and nonionic interfaces. One or more emulsifiers selected from activators [for example, Pluronic F68, HCO-60 (both are trade names), etc.] are preferably used. Particularly preferred is a fat emulsion using soybean oil as an oil and fat and egg yolk phospholipid as an emulsifier.

【0006】本発明の脂肪乳剤は平均粒子径が0.17μm
以下、好ましくは0.15μm以下であり、従来の脂肪乳剤
の平均粒子径0.2〜0.3μmに比べて微粒子化されている
ので高い安定性を有し、特に脂肪乳剤に糖類を配合した
輸液製剤においては、比重の相違による相分離を抑制で
きる。
The fat emulsion of the present invention has an average particle size of 0.17 μm.
The following is preferably 0.15 μm or less, and has high stability because it is finely divided as compared with the average particle diameter of a conventional fat emulsion of 0.2 to 0.3 μm, and in particular, in an infusion preparation containing a saccharide in a fat emulsion, The phase separation due to the difference in specific gravity can be suppressed.

【0007】本発明の脂肪乳剤の製造法は上記の特性を
有する脂肪乳剤の製造法であり、脂肪乳剤の調製時にグ
リセリン及びブドウ糖から選ばれた1種又は2種を添加
して乳化し、平均粒子径が0.17μm以下、好ましくは0.1
5μm以下である脂肪乳剤を調製するものである。従来か
ら脂肪乳剤の調製には、水に油脂及び乳化剤を加えた
後、撹拌して粗乳化液を調製し、次いで粗乳化液を高圧
乳化法等により乳化する方法が用いられているが、この
方法では通常、平均粒子径が0.2〜0.3μmの脂肪乳剤が
得られる。平均粒子径を更に小さくするには、乳化剤を
多量に使用すると共により過酷な条件(例えば、乳化機
通過回数を増やすと共に高圧で乳化する)で乳化させる
必要がある。しかし、乳化剤を多量に使用し過酷な条件
で乳化すると、脂肪乳剤中の遊離脂肪酸含量が増加し、
毒性の問題を生ずるので、栄養補給用脂肪乳剤として用
いることはできない。このような問題から、栄養補給用
脂肪乳剤の平均粒子径を小さくすることは困難であっ
た。しかしながら、発明者らはグリセリン及びブドウ糖
に微粒子化を促進する特異的な作用があることを見出し
たもので、本発明の製造法によれば平均粒子径が0.17μ
m以下である脂肪乳剤を容易に調製することができる。
本発明の製造法は、乳剤の調製時にグリセリン及びブド
ウ糖から選ばれた1種又は2種を添加する限り、種々の
態様で実施することができ、その一例を挙げると、水に
油脂及び乳化剤を加えると共にグリセリン及びブドウ糖
から選ばれた1種又は2種を加えた後、撹拌して粗乳化
液を調製し、次いで粗乳化液を高圧乳化法等の慣用の方
法により乳化することにより脂肪乳剤を調製することが
できる。上記の乳化を高圧乳化法で行なう場合、例え
ば、マントンゴーリンホモジナイザー等の乳化機を用
い、粗乳化液を20〜700Kg/cm2程度の条件下、5〜50回程
度、好ましくは10〜25回程度通過させることにより行わ
れる。なお、この方法において、グリセリン及び/又は
ブドウ糖は乳化する際に存在すればよく、例えば、油脂
と乳化剤とで調製した粗乳化液にグリセリン及び/又は
ブドウ糖を添加して乳化を行なってもよい。なお、得ら
れた乳剤の平均粒子径の測定は、光散乱法などの慣用の
測定法を用いることにより行なうことができる。
The method for producing a fat emulsion according to the present invention is a method for producing a fat emulsion having the above-mentioned characteristics. When the fat emulsion is prepared, one or two kinds selected from glycerin and glucose are added and emulsified. Particle size is 0.17μm or less, preferably 0.1
A fat emulsion having a size of 5 μm or less is prepared. Conventionally, for the preparation of a fat emulsion, a method of adding a fat and oil and an emulsifier to water, stirring to prepare a coarse emulsion, and then emulsifying the coarse emulsion by a high pressure emulsification method or the like is used. In the method, a fat emulsion having an average particle size of 0.2 to 0.3 μm is usually obtained. In order to further reduce the average particle diameter, it is necessary to use a large amount of an emulsifier and emulsify it under more severe conditions (for example, increasing the number of times of passage through an emulsifier and emulsifying at high pressure). However, when a large amount of emulsifier is used and emulsified under severe conditions, the free fatty acid content in the fat emulsion increases,
It cannot be used as a nutritional fat emulsion as it causes toxicity problems. Due to such problems, it was difficult to reduce the average particle size of the fat emulsion for nutritional supplement. However, the inventors have found that glycerin and glucose have a specific action of promoting micronization, and according to the production method of the present invention, the average particle size is 0.17 μm.
A fat emulsion having a size of m or less can be easily prepared.
The production method of the present invention can be carried out in various modes as long as one or two kinds selected from glycerin and glucose are added at the time of preparation of the emulsion. One example thereof is water containing fats and oils and an emulsifier. After adding 1 or 2 kinds selected from glycerin and glucose together with stirring, a crude emulsion is prepared by stirring, and then the crude emulsion is emulsified by a conventional method such as a high pressure emulsification method to form a fat emulsion. It can be prepared. When the above emulsification is carried out by a high-pressure emulsification method, for example, using an emulsifying machine such as Manton-Gaulin homogenizer, the crude emulsion is under conditions of about 20 to 700 Kg / cm 2, about 5 to 50 times, preferably 10 to 25 times. It is carried out by passing a degree. In this method, glycerin and / or glucose may be present at the time of emulsification, and for example, glycerin and / or glucose may be added to a crude emulsion prepared from fats and oils and an emulsifier for emulsification. The average grain size of the obtained emulsion can be measured by using a conventional measuring method such as a light scattering method.

【0008】上記の製造法において、油脂、乳化剤並び
にグリセリン及び/又はブドウ糖の使用量としては、得
られた脂肪乳剤が、油脂0.1〜30W/V%(以下、特別な明示
のない限り、%はW/V%を示す)程度、好ましくは2〜10%程
度、乳化剤0.01〜5.0%、好ましくは0.05〜3%程度、グリ
セリン及び/又はブドウ糖30〜70%程度、好ましくは40
〜60%程度、及び全量を100とするに必要な水とから構成
されるように調整して使用される。
In the above production method, the amount of fats and oils, emulsifiers and glycerin and / or glucose used is 0.1 to 30 W / V% of fats and oils (hereinafter, unless otherwise specified,% is W / V%), preferably about 2-10%, emulsifier 0.01-5.0%, preferably 0.05-3%, glycerin and / or glucose 30-70%, preferably 40.
It is used by adjusting it so that it is composed of about 60% and water necessary to make the total amount 100.

【0009】かくして得られた本発明の脂肪乳剤は、水
を用いて希釈したり、糖類を添加して糖濃度を調整する
等、所望に応じて適宜な形態としてもよい。上記の糖類
としては、輸液に用いられる糖類であれば種々の糖類を
用いることができるが、例えば、ブドウ糖、果糖、マル
トース、ソルビトール、キシリトール、グリセリン等が
挙げられる。糖類の濃度が調整された脂肪乳剤の組成の
好適な例としては、油脂0.1〜30%、好ましくは1〜20%、
より好ましくは2〜10%、乳化剤0.01〜5.0%、好ましくは
0.05〜3%、より好ましくは0.1〜1%、ブドウ糖、果糖、
マルトース、ソルビトール、キシリトール及びグリセリ
ンから選ばれた1種又は2種以上の糖類5〜60%、好まし
くは10〜40%、より好ましくは15〜30%、及び全量を100
とするに必要な水とから構成される脂肪乳剤が挙げられ
る。更に、本発明の脂肪乳剤には、滅菌時及び保存時の
pH低下や着色を防止するために、pH緩衝剤や着色防
止剤を添加してもよい。pH緩衝剤としては、例えば、
L−ヒスチジン、トリス(ヒドロキシメチル)アミノメ
タン等が、着色防止剤としては、例えば、チオグリセロ
ール、ジチオスレイトール等が例示される。これらのp
H緩衝剤及び着色防止剤の添加量は、通常、それぞれ1%
程度以下とされる。更に、ビタミン類(例えば、ビタミ
ンA、ビタミンB類、ビタミンC、ビタミンD類、ビタ
ミンE類、ビタミンK類等)などを添加してもよい。こ
れらの各種添加剤は、粗乳化液に添加してもよく、また
乳化後の脂肪乳剤に添加してもよい。本発明の脂肪乳剤
の液性としては、通常、pH5.0〜8.0程度、好ましくは
5.5〜7.0程度に調整される。
The thus obtained fat emulsion of the present invention may be in any suitable form such as dilution with water or addition of sugars to adjust the sugar concentration. As the saccharide, various saccharides can be used as long as they are used for infusion, and examples thereof include glucose, fructose, maltose, sorbitol, xylitol and glycerin. Suitable examples of the composition of the fat emulsion in which the concentration of sugars is adjusted, fats and oils 0.1 to 30%, preferably 1 to 20%,
More preferably 2-10%, emulsifier 0.01-5.0%, preferably
0.05-3%, more preferably 0.1-1%, glucose, fructose,
One or more sugars selected from maltose, sorbitol, xylitol and glycerin 5 to 60%, preferably 10 to 40%, more preferably 15 to 30%, and the total amount is 100.
A fat emulsion composed of water necessary for Further, the fat emulsion of the present invention may be added with a pH buffering agent or an anti-coloring agent in order to prevent the pH from lowering or coloring during sterilization and storage. As the pH buffering agent, for example,
L-histidine, tris (hydroxymethyl) aminomethane and the like, and examples of the color preventive agent include thioglycerol, dithiothreitol and the like. These p
The addition amount of H buffer and anti-coloring agent is usually 1% each.
It is considered to be below the level. Further, vitamins (eg, vitamin A, vitamin Bs, vitamin C, vitamin Ds, vitamin Es, vitamin Ks, etc.) may be added. These various additives may be added to the crude emulsion or the emulsified fat emulsion. The liquid property of the fat emulsion of the present invention is usually about pH 5.0 to 8.0, preferably
Adjusted to around 5.5-7.0.

【0010】本発明の脂肪乳剤及び本発明の製造法で得
られた脂肪乳剤は加熱滅菌することができ、加熱滅菌
は、例えば、当該輸液をガラス容器やプラスチック(例
えば、ポリプロピレン、ポリエチレン、エチレン−酢酸
ビニル共重合体、ポリ塩化ビニル等)容器(例えば、バ
ッグ、ボトル等)に充填し、次いで不活性ガス(例え
ば、窒素ガス、ヘリウムガス等)で置換し、密封した
後、滅菌工程に付すことにより行われる。滅菌工程は常
法に準じて行なうことができ、例えば、高圧蒸気滅菌、
熱水浸漬滅菌、熱水シャワー滅菌等の方法により行なう
ことができる。なお、プラスチック容器を用いる場合に
は、実質的に酸素を含まない雰囲気下で滅菌するのが好
ましい。
The fat emulsion of the present invention and the fat emulsion obtained by the production method of the present invention can be sterilized by heating. For example, the sterilization is carried out by subjecting the infusion solution to a glass container or a plastic (eg polypropylene, polyethylene, ethylene- (Vinyl acetate copolymer, polyvinyl chloride, etc.) Fill a container (eg, bag, bottle, etc.), then replace with an inert gas (eg, nitrogen gas, helium gas, etc.), seal, and then sterilize It is done by The sterilization step can be performed according to a conventional method, for example, high pressure steam sterilization,
It can be carried out by a method such as hot water immersion sterilization or hot water shower sterilization. When using a plastic container, it is preferable to sterilize in an atmosphere containing substantially no oxygen.

【0011】本発明の脂肪乳剤及び本発明の製造法で得
られた脂肪乳剤は栄養補給を目的として生体に投与する
ことができ、そのままで若しくは水で希釈して、又単独
で若しくは必要に応じて他のアミノ酸輸液、電解質輸液
等と混合されて患者に経静脈投与される。更に経口、経
腸等の投与形態での投与にも用いることができる。
The fat emulsion of the present invention and the fat emulsion obtained by the production method of the present invention can be administered to a living body for the purpose of nutritional supplementation, and may be used as it is or diluted with water, or alone or as needed. It is mixed with other amino acid infusions, electrolyte infusions, etc. and administered intravenously to the patient. Furthermore, it can be used for administration in a dosage form such as oral administration and enteral administration.

【0012】[0012]

【実施例】以下、実施例に基づいて本発明をより詳細に
説明するが、本発明はこれらの実施例に限定されるもの
ではない。 実施例1 大豆油及び卵黄リン脂質を含む分散液に、グリセリン又
は各種糖(ブドウ糖、ソルビトール、キシリトール又は
果糖)を添加し粗乳化した後、マントンゴーリンホモジ
ナイザー(ゴーリン社製、15M-8TA型)により乳化(圧
力:550Kg/cm2、液温:70℃以下)して、下記表1に示さ
れる組成の脂肪乳剤を調製した。この際、乳化中におけ
る乳剤の平均粒子径を経時的に測定した。なお、平均粒
子径の測定は、乳剤0.1mlに水100mlを加えて試料溶液と
し、この試料溶液についてマルバーンオートサイザー2C
(マルバーン社製)を用いて行った。また、対照とし
て、グリセリン及び糖類の代りに同量の水を用いて同様
の試験を行った。その結果を図1に示す。なお、図1
中、●はグリセリン、◆はブドウ糖、○はソルビトー
ル、□はキシリトール、▽は果糖、△は対照をそれぞれ
示す。
The present invention will be described in more detail based on the following examples, but the invention is not intended to be limited to these examples. Example 1 Glycerin or various sugars (glucose, sorbitol, xylitol, or fructose) was added to a dispersion liquid containing soybean oil and egg yolk phospholipid, and the mixture was coarsely emulsified. The emulsion was emulsified (pressure: 550 Kg / cm 2 , liquid temperature: 70 ° C. or lower) to prepare a fat emulsion having the composition shown in Table 1 below. At this time, the average particle size of the emulsion during emulsification was measured over time. The average particle size was measured by adding 100 ml of water to 0.1 ml of emulsion to prepare a sample solution, and using this sample solution, Malvern Autosizer 2C
(Manufactured by Malvern Instruments Ltd.). As a control, the same test was conducted using the same amount of water instead of glycerin and saccharides. The result is shown in FIG. Note that FIG.
Middle, ● indicates glycerin, ◆ indicates glucose, ○ indicates sorbitol, □ indicates xylitol, ▽ indicates fructose, and △ indicates control.

【0013】 [0013]

【0014】図1に示されるように、対照系(グリセリ
ン及び糖類を含まない系)においては、乳化機通過回数
が30回になっても平均粒子径は0.2μm程度であった。
また、ソルビトール、キシリトール及び果糖をそれぞれ
含む系においても、乳化機通過回数30回における平均
粒子径は0.18〜0.2μm程度であった。それに対して、グ
リセリン及びブドウ糖を含む系においては、乳化機通過
回数に応じて平均粒子径が急速に低下しており、グリセ
リンを含む系においては乳化機通過回数約8回で、ブド
ウ糖を含む系においては乳化機通過回数約20回で平均
粒子径が0.17μm以下となった。このことから、グリセ
リン及びブドウ糖は、粒子径を低下させる特異的な作用
を有することが明らかとなった。
As shown in FIG. 1, in the control system (system not containing glycerin and saccharide), the average particle size was about 0.2 μm even when the number of passages through the emulsifying machine was 30 times.
Further, also in the systems containing sorbitol, xylitol and fructose, the average particle size after passing through the emulsifying machine 30 times was about 0.18 to 0.2 μm. On the other hand, in the system containing glycerin and glucose, the average particle size was rapidly decreased in accordance with the number of times the emulsifier passed, and in the system containing glycerin, the system containing glucose was about 8 times passed through the emulsifier. In the above, the average particle diameter became 0.17 μm or less after passing through the emulsifying machine about 20 times. From this, it became clear that glycerin and glucose have a specific action of reducing the particle size.

【0015】実施例2 大豆油60g、卵黄リン脂質7.2g及びブドウ糖500gを水に
加え粗乳化した後、水で全量を1000mlとした。得られた
粗乳化液を、マントンゴーリンホモジナイザー(ゴーリ
ン社製、15M-8TA型)により平均粒子径が0.15μm以下と
なるまで乳化して脂肪乳剤を調製した。この脂肪乳剤50
0mlに水500mlを加えた。得られた脂肪乳剤の組成を表2
に示す。この製剤を50mlのガラス容器に分注し、窒素ガ
スで置換した後、施栓し、次いで115℃、30分間の高圧
蒸気滅菌を施した。滅菌前後の性状、pH及び乳剤の平
均粒子径を比較した。その結果を表3に示す。
Example 2 Soybean oil (60 g), egg yolk phospholipid (7.2 g) and glucose (500 g) were added to water for coarse emulsification, and the total amount was adjusted to 1000 ml with water. The obtained crude emulsion was emulsified with a Manton Gorin homogenizer (manufactured by Gorin Co., 15M-8TA type) until the average particle diameter became 0.15 μm or less to prepare a fat emulsion. This fat emulsion 50
500 ml of water was added to 0 ml. The composition of the obtained fat emulsion is shown in Table 2.
Shown in. This formulation was dispensed into a 50 ml glass container, purged with nitrogen gas, stoppered, and then subjected to high-pressure steam sterilization at 115 ° C. for 30 minutes. The properties before and after sterilization, pH and the average particle size of the emulsion were compared. The results are shown in Table 3.

【0016】 [0016]

【0017】 [0017]

【0018】表3に示されるように、滅菌によりpHは
わずかに低下したが、製剤は安定であった。
As shown in Table 3, sterilization resulted in a slight decrease in pH but the formulation was stable.

【0019】実施例3 大豆油42.64g及び卵黄リン脂質6.14gを70℃に加温し、7
0%ブドウ糖液429ml(70℃)を加えた後、水にて全量を500
mlに調整し、粗乳化した。次いでマントンゴーリンホモ
ジナイザー(ゴーリン社製、15M-8TA型)を用いて乳化し
(圧力:550Kg/cm2、液温:70℃以下)、平均粒子径が0.1
7μm以下の脂肪乳剤を得た。
Example 3 42.64 g of soybean oil and 6.14 g of egg yolk phospholipid were heated to 70 ° C.
After adding 429 ml (70 ° C) of 0% glucose solution, bring the total volume to 500 with water.
It was adjusted to ml and coarsely emulsified. Then emulsified using a Manton Gorin homogenizer (manufactured by Gorin Co., 15M-8TA type) (pressure: 550 Kg / cm 2 , liquid temperature: 70 ° C. or lower), the average particle diameter is 0.1.
A fat emulsion of 7 μm or less was obtained.

【0020】実施例4 実施例3で得られた脂肪乳剤150mlに注射用水を加えて
全量を500mlとした後、50mlのガラス容器に分注し、窒
素ガスで置換した後、施栓し、次いで115℃、30分間の
高圧蒸気滅菌を施した。かくして得られた製剤は、良好
な乳化状態を長期間維持することができた。
Example 4 150 ml of the fat emulsion obtained in Example 3 was added with water for injection to make a total volume of 500 ml, dispensed in a 50 ml glass container, replaced with nitrogen gas, capped and then 115 High-pressure steam sterilization was performed at 30 ° C for 30 minutes. The preparation thus obtained was able to maintain a good emulsified state for a long period of time.

【0021】実施例5 実施例3で得られた脂肪乳剤200mlに注射用水304ml及び
70%ブドウ糖液13.2mlを加えた後、50mlのガラス容器に
分注し、窒素ガスで置換した後、施栓し、次いで115
℃、30分間の高圧蒸気滅菌を施した。かくして得られた
製剤は、良好な乳化状態を長期間維持することができ
た。
Example 5 To 200 ml of the fat emulsion obtained in Example 3, 304 ml of water for injection and
After adding 13.2 ml of 70% glucose solution, the mixture was dispensed into a 50 ml glass container, replaced with nitrogen gas, and then stoppered, then 115
High-pressure steam sterilization was performed at 30 ° C for 30 minutes. The preparation thus obtained was able to maintain a good emulsified state for a long period of time.

【0022】[0022]

【発明の効果】以上のように、本発明の脂肪乳剤は平均
粒子径が0.17μm以下に調整されており、脂肪乳剤の滅
菌時及び保存時の安定性の著しい向上が図れると共に他
の輸液剤と混合した際においても良好な乳化状態を長期
間保持することができる。また、本発明の製造法によれ
ば、多量の乳化剤を使用しなくとも、上記の特性を有す
る脂肪乳剤を簡便且つ確実に調製することができる。従
って、本発明によれば、長期にわたり安定性及び安全性
に優れた脂肪乳剤を提供でき、特に、脂肪乳剤に糖類を
配合した輸液製剤においては、比重の相違による相分離
を抑制でき、しかも使用時に脂肪乳剤と糖類とを配合す
る操作を必要としないので、操作が簡便化されると共に
混合時の菌汚染を防止できるという効果を奏する。
As described above, the fat emulsion of the present invention is adjusted to have an average particle size of 0.17 μm or less, and the stability of the fat emulsion during sterilization and storage can be remarkably improved and other infusion solutions can be obtained. Even when mixed with, a good emulsified state can be maintained for a long period of time. Further, according to the production method of the present invention, a fat emulsion having the above characteristics can be prepared simply and reliably without using a large amount of an emulsifier. Therefore, according to the present invention, it is possible to provide a fat emulsion excellent in stability and safety for a long period of time, and particularly in an infusion preparation in which a saccharide is mixed with a fat emulsion, phase separation due to a difference in specific gravity can be suppressed, and use Since the operation of blending the fat emulsion and the saccharide is not necessary at the time, the operation is simplified and the effect of preventing bacterial contamination during mixing can be obtained.

【図面の簡単な説明】[Brief description of drawings]

図1は、実施例1の脂肪乳剤の調製において、乳化機通
過回数と脂肪乳剤の平均粒子径との関係を示す図であ
る。同図中、●はグリセリン、◆はブドウ糖、○はソル
ビトール、□はキシリトール、▽は果糖、△は対照をそ
れぞれ示す。
FIG. 1 is a graph showing the relationship between the number of passages through an emulsifying machine and the average particle size of a fat emulsion in the preparation of the fat emulsion of Example 1. In the figure, ● indicates glycerin, ◆ indicates glucose, ○ indicates sorbitol, □ indicates xylitol, ▽ indicates fructose, and △ indicates control.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31/045 8413−4C 31/23 8413−4C 31/70 ADD 8314−4C 47/06 H 7329−4C (72)発明者 村島 良一郎 枚方市招提大谷二丁目25番1号 株式会社 ミドリ十字中央研究所内 (72)発明者 阿部 俊一 枚方市招提大谷二丁目25番1号 株式会社 ミドリ十字中央研究所内 (72)発明者 横山 和正 枚方市招提大谷二丁目25番1号 株式会社 ミドリ十字中央研究所内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification number Office reference number FI technical display location A61K 31/045 8413-4C 31/23 8413-4C 31/70 ADD 8314-4C 47/06 H 7329 −4C (72) Inventor Ryoichiro Murashima Invited 2-25-1 Otani, Hirakata City, Midori Cross Central Research Institute Co., Ltd. (72) Inventor Shunichi Abe Invited 2-25 Otani, Hirakata City Central Research Institute, Midori Cross Co., Ltd. (72) Inventor Kazumasa Yokoyama 2-25-1 Otani, Hirakata-shi, Midori Cross Central Research Institute

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 油脂を乳化剤を用いて乳化させた栄養
補給用脂肪乳剤であって、乳化剤含量が0.01〜5.0W/V%
であり、脂肪乳剤の平均粒子径が0.17μm以下であるこ
とを特徴とする脂肪乳剤。
1. A fat emulsion for nutritional supplementation, in which fats and oils are emulsified with an emulsifier, and the emulsifier content is 0.01 to 5.0 W / V%.
And the mean particle size of the fat emulsion is 0.17 μm or less.
【請求項2】 脂肪乳剤が、油脂0.1〜30W/V%、乳化
剤0.01〜5W/V%、ブドウ糖及びグリセリンから選ばれた
1種又は2種30〜70W/V%及び全量を100とするに必要な
水とからなる請求項1記載の脂肪乳剤。
2. The fat emulsion comprises 0.1 to 30 W / V% of oil and fat, 0.01 to 5 W / V% of emulsifier, 30 to 70 W / V% of one or two kinds selected from glucose and glycerin, and the total amount is 100. A fat emulsion according to claim 1 consisting of the required water.
【請求項3】 脂肪乳剤が、油脂0.1〜30W/V%、乳化
剤0.01〜5W/V%、ブドウ糖、果糖、マルトース、ソルビ
トール、キシリトール及びグリセリンから選ばれた1種
又は2種以上5〜60W/V%及び全量を100とするに必要な水
とからなる請求項1記載の脂肪乳剤。
3. The fat emulsion comprises one or more selected from oils and fats 0.1 to 30 W / V%, emulsifiers 0.01 to 5 W / V%, glucose, fructose, maltose, sorbitol, xylitol and glycerin, and 5 to 60 W /. The fat emulsion according to claim 1, which comprises V% and water necessary to bring the total amount to 100.
【請求項4】 油脂が植物油、魚油、中鎖脂肪酸トリ
グリセリド及び化学合成トリグリセリドから選ばれた1
種又は2種以上であり、乳化剤が卵黄リン脂質、水素添
加卵黄リン脂質、大豆リン脂質、水素添加大豆リン脂質
及び非イオン性界面活性剤から選ばれた1種又は2種以
上である請求項1から3のいずれかに記載の脂肪乳剤。
4. A fat and oil selected from vegetable oil, fish oil, medium chain fatty acid triglyceride and chemically synthesized triglyceride.
Or 2 or more, and the emulsifier is 1 or 2 or more selected from egg yolk phospholipids, hydrogenated egg yolk phospholipids, soybean phospholipids, hydrogenated soybean phospholipids and nonionic surfactants. The fat emulsion according to any one of 1 to 3.
【請求項5】 油脂を、グリセリン及びブドウ糖から
選ばれた1種又は2種とともに乳化剤を用いて乳化し、
平均粒子径が0.17μm以下の脂肪乳剤を得ることを特徴
とする栄養補給用脂肪乳剤の製造法。
5. An oil and fat is emulsified with one or two kinds selected from glycerin and glucose using an emulsifier,
A method for producing a fat emulsion for nutritional supplementation, which comprises obtaining a fat emulsion having an average particle size of 0.17 μm or less.
【請求項6】 植物油、魚油、中鎖脂肪酸トリグリセ
リド及び化学合成トリグリセリドから選ばれた1種又は
2種以上の油脂を、グリセリン及びブドウ糖から選ばれ
た1種又は2種とともに、卵黄リン脂質、水素添加卵黄
リン脂質、大豆リン脂質、水素添加大豆リン脂質及び非
イオン性界面活性剤から選ばれた1種又は2種以上の乳
化剤を用いて乳化させる請求項5記載の栄養補給用脂肪
乳剤の製造法。
6. Egg yolk phospholipid, hydrogen together with 1 or 2 or more kinds of fats and oils selected from vegetable oil, fish oil, medium chain fatty acid triglyceride and chemically synthesized triglyceride, together with 1 or 2 kinds selected from glycerin and glucose. The production of a fat emulsion for nutritional supplementation according to claim 5, which is emulsified with one or more emulsifiers selected from added egg yolk phospholipids, soybean phospholipids, hydrogenated soybean phospholipids and nonionic surfactants. Law.
JP3222031A 1991-04-26 1991-08-06 Fat emulsion and method for producing the same Expired - Fee Related JP2950348B2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
JP3222031A JP2950348B2 (en) 1991-04-27 1991-08-06 Fat emulsion and method for producing the same
DK92107054T DK0510687T3 (en) 1991-04-26 1992-04-24 infusion
EP95104553A EP0671166B1 (en) 1991-04-26 1992-04-24 Nutrient-supplying infusion
EP92107054A EP0510687B1 (en) 1991-04-26 1992-04-24 Infusion preparation
DK95104553T DK0671166T3 (en) 1991-04-26 1992-04-24 Nutritional Preparations
CA002067062A CA2067062C (en) 1991-04-26 1992-04-24 Infusion preparation
DE69232811T DE69232811T2 (en) 1991-04-26 1992-04-24 Infustionspräparat
ES92107054T ES2181669T3 (en) 1991-04-26 1992-04-24 INFUSION PREPARATION.
DE69232957T DE69232957T2 (en) 1991-04-26 1992-04-24 Containers filled with liquid infusions
ES96115944T ES2188704T3 (en) 1991-04-26 1992-04-24 CONTAINER FILLING WITH INFUSION LIQUIDS.
EP96115944A EP0752243B1 (en) 1991-04-26 1992-04-24 Container filled with infusion liquids
DE69233437T DE69233437T2 (en) 1991-04-26 1992-04-24 Infusion for delivery of food
DK96115944T DK0752243T3 (en) 1991-04-26 1992-04-24 Container filled with infusion solutions
KR1019920007018A KR920019370A (en) 1991-04-26 1992-04-25 Infusion preparations
TW081103293A TW320563B (en) 1991-04-26 1992-04-25
US08/475,812 US5972367A (en) 1991-04-26 1995-06-07 Infusion preparation
US08/478,970 US5674527A (en) 1991-04-26 1995-06-07 Infusion preparation comprising phospholipid
US08/589,207 US5626880A (en) 1991-04-26 1996-01-22 Infusion preparation
US09/244,931 US6475506B1 (en) 1991-04-26 1999-02-10 Infusion preparation
KR1019990023090A KR100244997B1 (en) 1991-04-26 1999-06-19 A container filled with infusion liquids
KR1019990062610A KR100489158B1 (en) 1991-04-26 1999-12-27 Intravenous injection preparation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12486391 1991-04-27
JP3-124863 1991-04-27
JP3222031A JP2950348B2 (en) 1991-04-27 1991-08-06 Fat emulsion and method for producing the same

Publications (2)

Publication Number Publication Date
JPH059111A true JPH059111A (en) 1993-01-19
JP2950348B2 JP2950348B2 (en) 1999-09-20

Family

ID=26461431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3222031A Expired - Fee Related JP2950348B2 (en) 1991-04-26 1991-08-06 Fat emulsion and method for producing the same

Country Status (1)

Country Link
JP (1) JP2950348B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025059A1 (en) * 1993-04-30 1994-11-10 The Green Cross Corporation Nutritional transfusion for peripheral vein administration
JP2013526847A (en) * 2010-03-26 2013-06-27 コーンプロダクツ ディベロップメント インコーポレーテッド Emulsions useful in beverages
JPWO2011118810A1 (en) * 2010-03-26 2013-07-04 味の素株式会社 Nutritional composition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025059A1 (en) * 1993-04-30 1994-11-10 The Green Cross Corporation Nutritional transfusion for peripheral vein administration
JP2013526847A (en) * 2010-03-26 2013-06-27 コーンプロダクツ ディベロップメント インコーポレーテッド Emulsions useful in beverages
JPWO2011118810A1 (en) * 2010-03-26 2013-07-04 味の素株式会社 Nutritional composition

Also Published As

Publication number Publication date
JP2950348B2 (en) 1999-09-20

Similar Documents

Publication Publication Date Title
Collins-Gold et al. Parenteral emulsions for drug delivery
US5626880A (en) Infusion preparation
US4486417A (en) Flurocarbon-water emulsion for hyperalimentation containing maltose
TWI321989B (en) Water-soluble composition containing coenzyme q10
JPWO2011118810A1 (en) Nutritional composition
EA006141B1 (en) Preparation of vitamin emulsions and concentrates thereof
EP0752243B1 (en) Container filled with infusion liquids
CA2526567A1 (en) Oil emulsion for postnatal hormone substitution
EP0220152A1 (en) Fat emulsion
KR20170071467A (en) Application of Large-Dose Glycerinum in Freeze-Thawing Tolerable Lipid Emulsion
JP2004196781A (en) Water-soluble composition containing coenzyme q10
TWI598093B (en) A stable composition containing high concentiation coenzyme q10
US5677341A (en) Emulsion suitable for administering a sphingolipid
JPS58162517A (en) Fat-soluble vitamin-containing fatty emulsion
JP3109161B2 (en) Infusion preparation
JP2950348B2 (en) Fat emulsion and method for producing the same
JP3446035B2 (en) Infusion preparation
JP4518042B2 (en) Method for producing water-soluble composition containing coenzyme Q10
JP3097196B2 (en) Stabilization of fat emulsion
JP2940249B2 (en) Infusion preparation
CN115634198A (en) Solvent composition for water-insoluble substances and preparation method and application thereof
JP2769587B2 (en) Powder nutrition composition
JP3456536B2 (en) Infusion preparation
JP3172293B2 (en) Liquid sterile nutrition composition
JP3236373B2 (en) Liquid enteral nutrition in the form of a kit composed of multiple liquids

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080709

Year of fee payment: 9

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080709

Year of fee payment: 9

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080709

Year of fee payment: 9

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees